John W. Childs - 10 Nov 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role: Director
Signature: /s/ Jim Engelhart, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 10 Nov 2021
Net transactions value: +$614,342
Form type: 4
Filing time: 10 Nov 2021, 17:19:09 UTC
Previous filing: 07 May 2021
Next filing: 17 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Purchase	$477,480	+3,890	+0.15%	$122.75^*	2,549,691	10 Nov 2021	Direct	F1
transaction	BHVN	Common Shares	Purchase	$136,862	+1,110	+0.04%	$123.30^*	2,550,801	10 Nov 2021	Direct	F2
holding	BHVN	Common Shares						10,000	10 Nov 2021	By John W Childs 2013 Revocable Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $122.45 - $123.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2	The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $123.16 - $123.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $122.45 - $123.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $123.16 - $123.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.